Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
46 articles with Altimmune, Inc.
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
Altimmune to Present at Upcoming Scientific Conferences
4/29/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021.
-
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
4/1/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.
-
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
3/15/2021
New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months
-
Altimmune to Present at Upcoming Conferences
3/8/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021.
-
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
2/25/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced enrollment in a Phase 1 clinical trial of AdCOVID, a single-dose intranasal COVID-19 vaccine candidate.
-
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
2/25/2021
Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through the Phase 1 Clinical Trial Solidly Capitalized to Advance Pipeline Candidates with $216 Million in Cash and Short-Term Investments at Year-End
-
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
2/22/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
-
Altimmune Announces FDA Clearance of AdCOVID™ IND ApplicationEnrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week
2/17/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate.
-
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
-
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
12/30/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB). The study is being conducted in the United States, Canada and Europe and is a double-blind, randomized, placebo-controlled study of 80 adult patients with
-
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
12/23/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug (IND) application for AdCOVID, a single-dose intranasal COVID-19 vaccine candidate. The Agency requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls (CMC) data. Altimmune has res
-
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
12/11/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune will give an oral presentation on ALT-801, the Company’s novel GLP-1/Glucagon dual receptor agonist in development for the treatment of non-alcoholic steatohepatitis (NASH.)
-
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
12/8/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801. ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the United States. The Ph
-
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
11/25/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
-
Altimmune to Present at Upcoming Virtual Investor Conferences
11/16/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences: Jefferies London Virtual Healthcare Conference Tuesday, November 17, 2020 11:25 am Eastern Time Piper Sandler 32 nd Annual Virtual Healthcare Conference Monday, November
-
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
11/9/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update.
-
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
11/3/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020. Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update. Conference Call Details Date: Tuesday, November 10th Time: 8:30
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID™ and T-COVID™ – at the World Vaccine Congress
9/28/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts, Ph.D., Chief Scientific Officer of Altimmune, Inc., presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine and therapeutic candidates during a special COVID-19 virtual session of the World Vaccine Congress Washington, taking place September 28 – October 1, 2020. A link to Dr. Roberts’ presentation is availab